Jefferies Financial Group Reiterates Buy Rating for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Financial Group in a report issued on Monday, ThisIsMoney.Co.Uk reports.

Other research analysts have also recently issued research reports about the company. Liberum Capital restated a “hold” rating on shares of GlaxoSmithKline in a research report on Thursday, May 28th. JPMorgan Chase & Co. decreased their price target on GlaxoSmithKline from GBX 1,750 ($21.54) to GBX 1,700 ($20.92) and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Citigroup restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, June 18th. Morgan Stanley decreased their price target on GlaxoSmithKline from GBX 1,740 ($21.41) to GBX 1,725 ($21.23) and set an “underweight” rating on the stock in a research report on Tuesday, March 3rd. Finally, Oddo Securities raised their price target on GlaxoSmithKline from GBX 1,760 ($21.66) to GBX 1,840 ($22.64) and gave the stock a “neutral” rating in a research report on Monday, June 22nd. Three analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of GBX 1,849.88 ($22.76).

GSK opened at GBX 1,636.60 ($20.14) on Monday. GlaxoSmithKline has a fifty-two week low of GBX 1,328.19 ($16.34) and a fifty-two week high of GBX 1,857 ($22.85). The company has a debt-to-equity ratio of 159.26, a quick ratio of 0.54 and a current ratio of 0.87. The company has a market capitalization of $83.51 billion and a P/E ratio of 15.56. The stock has a fifty day moving average of GBX 1,652.73 and a 200-day moving average of GBX 1,662.60.

GlaxoSmithKline (LON:GSK) last posted its earnings results on Wednesday, April 29th. The company reported GBX 37.70 ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of GBX 31.10 ($0.38) by GBX 6.60 ($0.08). On average, equities research analysts predict that GlaxoSmithKline will post 11381.5620093 earnings per share for the current fiscal year.

In other news, insider Emma Walmsley purchased 28 shares of GlaxoSmithKline stock in a transaction dated Thursday, April 9th. The shares were bought at an average cost of GBX 1,536 ($18.90) per share, for a total transaction of £430.08 ($529.26).

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Article: Google Finance

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.